RCKT ▲ +0.6% - Rocket Pharmaceuticals, Inc. $RCKT Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease Rocket Pharmaceuticals rose 0.6% after announcing FDA alignment on its development plan for RP-A501, a gene therapy candidate in a pivotal Phase 2 trial for Danon disease, a rare genetic disorder affecting heart and skeletal muscle. The FDA agreement on the trial's path forward reduces regulatory uncertainty and supports the company's ability to advance the program toward potential approval. 15-SEP-2026 07:03 AM ET